The role of exercise and PGC1alpha in inflammation and chronic disease by Handschin, Christoph & Spiegelman, Bruce M.
Institutional Repository of the University of Basel 
University Library
Schoenbeinstrasse 18-20
CH-4056 Basel, Switzerland 
http://edoc.unibas.ch/
Year: 2008 
The role of exercise and PGC1alpha in inflammation and chronic 
disease 
Handschin, Christoph and Spiegelman, Bruce M. 
Posted at edoc, University of Basel 
Official URL: http://edoc.unibas.ch/dok/A5258709 
Originally published as: 
Handschin, Christoph and Spiegelman, Bruce M.. (2008) The role of exercise and PGC1alpha in 
inflammation and chronic disease. Nature, Vol. 454. S. 463-469. 
The role of exercise and PGC1α in inflammation and 
chronic disease 
Christoph Handschin1 and Bruce M. Spiegelman2
1Institute of Physiology and Zurich Center for Integrative Human Physiology (ZIHP), 
University of Zurich, CH-8057 Zurich, Switzerland 
2Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical 
School, Boston, MA 02115, USA 
Published in Nature. 2008 Jul 24;454(7203):463-9. PMID: 18650917. doi: 10.1038/nature07206. 
Copyright © Nature Publishing Group; Nature 
1 
The role of exercise and PGC1α in inflammation and 
chronic disease 
Christoph Handschin1 and Bruce M. Spiegelman2 
1Institute of Physiology and Zurich Center for Integrative Human Physiology (ZIHP), 
University of Zurich, CH-8057 Zurich, Switzerland 
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Inadequate physical activity is linked to many chronic diseases. However, the 
mechanisms that tie muscle activity to health are unclear. The peroxisome 
proliferator-activated receptor γ co-activator 1α (PGC-1α) controls several 
exercise-related aspects of muscle function. We propose here mechanisms by which 
this protein controls muscle plasticity, suppresses a broad inflammatory response 
and mediates the beneficial effects of exercise. 
The reduction in physical activity, resulting from shifts in the nature of work and the 
replacement of muscle with machine in the developed world, has driven a dramatic 
increase in the incidence of many chronic diseases. In addition to the more obvious 
consequences associated with reduced activity, such as obesity, cardiovascular diseases, 
hypertension and type 2 diabetes, lack of sufficient exercise has also been linked to 
certain important types of cancer, pulmonary diseases, immune dysfunction, 
musculoskeletal diseases and several types of neurodegenerative disorders1 (Fig. 1). In 
fact, a sedentary lifestyle is a major risk factor for many chronic pathologies and it has 
been shown unequivocally that inactivity increases the morbidity and mortality of these 
diseases2,3. Exercise capacity is a strong predictor of overall mortality, regardless of 
health and race4. Unfortunately, more than 50% of US adults do not exercise enough to 
achieve health benefits and 25% of adults shun any form of physical activity in their 
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leisure time (Source: Center for Disease Control and Prevention, www.cdc.gov)5; 
especially alarming is the rising trend of physical inactivity among young people6. 
Devastating effects of insufficient physical activity are likewise observed in the elderly7. 
Decreased muscle function in this population is not only directly linked to sarcopenia 
and the prevalence of a number of chronic diseases, but contributes enormously to the 
overall quality of life by diminishing strength, the ability to perform daily chores and 
social interactions, mobility, cognitive performance and life expectancy7. Even in the 
early elderly years, changes in physical activity have drastic consequences for health 
and lifespan. For example, sedentary behaviour in a 70-year-old man reduces the 
probability of survival to age 90 from 54% to 44%8. In contrast, increasing physical 
activity is an effective preventative measure for many chronic disorders. Furthermore, 
exercise is an excellent therapeutic intervention for pathologies such as obesity, type 2 
diabetes, neurodegeneration, osteoporosis and sarcopenia1; in terms of efficacy, exercise 
can rival the effects of drugs that are prescribed for many of these diseases, e.g. type 2 
diabetes9. 
Inactivity, inflammation and chronic disease 
Many chronic diseases have been found to be associated with a sterile, persistent, low-
grade inflammation (Fig. 2). For example, the development of insulin resistance and 
type 2 diabetes tissue is closely correlated with immune cell infiltration and 
inflammation in white adipose tissue10. In cardiovascular diseases, activated immune 
cells and inflammation play a major role, particularly in the etiology of 
atherosclerosis11,12. Importantly, tumor initiation, promotion, and progression is 
stimulated by systemic elevation of pro-inflammatory cytokines13. 
A number of neurodegenerative diseases are linked to a local inflammatory 
response in the brain (neuroinflammation). For example, neuroinflammation influences 
activation of glia cells and subsequent release of pro-inflammatory cytokines such as 
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tumor necrosis factor α (TNFα); these are thought to promote the death of 
dopaminergic neurons in the substantia nigra and thereby contribute to the pathology of 
Parkinson’s disease14,15. Similarly, interleukin-1β (IL-1β), TNF-related apoptosis-
inducing ligand (TRAIL) and other cytokines have been postulated to be involved in the 
etiology of Alzheimer’s disease16, as has amyloid-β, itself exhibiting pro-inflammatory 
effects17. It is important to note that in addition to the neuroinflammation found in many 
neurodegenerative disorders, systemic inflammation further exacerbates these diseases 
and promotes the progression of neurodegeneration18. 
Physical activity, inflammation and immunity are tightly linked in an interesting 
and complex way19. Regular, moderate exercise reduces systemic inflammation20. The 
mediators of this beneficial effect of exercise are unclear; however, several candidate 
mechanisms have been identified. First, exercise increases the release of epinephrine, 
cortisol, growth hormone, prolactin and other factors that have immunomodulatory 
effects21. Furthermore, exercise results in decreased expression of Toll-like receptor on 
monocytes suggested to be involved in mediating whole body inflammation22. In 
contrast to the reduction of chronic inflammation by regular, moderate exercise, 
prolonged, high intensity training results in increased systemic inflammation and 
elevated risk of infection20. In fact, subsequent to this type of exercise, athletes exhibit a 
transient exercise-induced immunodepression23. 
The recent discovery of “myokines”, cytokines produced and secreted from 
skeletal muscle, analogous to “adipokines” made from fat tissue, shed light on this 
bivalent association between exercise and inflammation19. The first myokine to be 
described was interleukin-6 (IL-6); similar factors synthesized and secreted upon 
contraction of muscle fibers include IL-8 and IL-1524. In addition to these muscle-
derived cytokines, increased IL-1 receptor antagonist (IL-1ra), IL-10 and TNFα are 
found in the circulation after exercise24. However, systemic elevation of TNFα is 
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restricted to physical activity of extremely high intensity and therefore could be 
responsible for the elevated inflammatory state upon prolonged, intense exercise. 
Once released transiently into the blood stream, myokines mediate some of the 
systemic and beneficial effects of exercise in non-muscle tissue, e.g. modulation of 
hepatic glucose production through IL-6. Some of these cytokines are clearly pro- (e.g. 
IL-1, TNFα) or anti-inflammatory (e.g. IL-10, IL-1ra). Paradoxically, both pro- and 
anti-inflammatory effects have been attributed to others25. For example, chronically 
elevated serum IL-6 levels have a predictive value for obesity and type 2 diabetes. In 
addition, chronically elevated levels of systemic IL-6, IL-8, IL-10, IL-1 and TNFα have 
been linked to the development of many diseases associated with inflammation 
including cancer, and other age-associated diseases, such as sarcopenia, 
neurodegeneration and depression10,11,13,26-28. Finally, chronic elevation of IL-6 and 
TNFα results in skeletal muscle atrophy and inhibition of muscle regeneration, 
respectively29,30. Thus, the transient fluctuations of myokines following physical activity 
might contribute to the beneficial effects of exercise on organs other than muscle in a 
hormone-like fashion, whereas chronic elevation of many of these same molecules is 
almost certainly pro-inflammatory and detrimental. Obviously, then, the increase of IL-
6 and other cytokines secreted from muscle in exercise and their subsequent return to 
basal levels must be tightly regulated. 
Effects of endurance and strength training 
Distinct exercise regimens are useful for the prevention and treatment of different 
pathologies. For example, endurance training improves cardiovascular parameters31, 
strength training reduces sarcopenia32, and the combination of both training regiments 
was recently reported to be the most beneficial paradigm for type 2 diabetic patients33. 
For other diseases, the optimal training form remains to be defined. It is clear that 
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sedentary behaviour increases the risk for developing certain types of cancer1,34. 
Likewise, the type of exercise that confers the greatest protection against 
neurodegenerative diseases is unknown. Interestingly, moderate exercise (e.g. walking) 
is sufficient to reduce the risk of developing dementia, as shown in a prospective study 
with persons 65 years of age or older35. 
Mechanistically, resistance training and endurance exercise activate distinct 
signalling pathways and result in specific adaptations of skeletal muscle. A significant 
proportion of the capacity for adaptations of skeletal muscle is determined by the 
relative number and cross-sectional area of different muscle fiber types within a 
particular muscle bed36. Endurance is improved with increased numbers of type I and 
type IIa fibers and endurance training increases the number of these fibers. Type I and 
type IIa fibers are red in appearance and are characterized by a high number of 
mitochondria, elevated myoglobin and vascularization, and express a specific set of 
myofibrillar proteins. As a result, they display resistance to fatigue and slow 
contractions with low peak force generation37. The main source of ATP is the oxidative 
phosphorylation of glucose and fatty acids. In contrast, the white type IIb fibers (type 
IIx fibers in humans) have a relatively low number of mitochondria and mainly use 
anaerobic phosphocreatine and glucose metabolism to generate ATP. These fibers 
fatigue rapidly, but are able to generate fast contractions with a high peak force37. When 
stimulated by strength training, type IIb muscle fibers can undergo substantial 
hypertrophy38. 
Regulation and role of the PGC-1 coactivators in skeletal muscle physiology 
Contraction of skeletal muscle is initiated by motor neuron-induced calcium signalling. 
The adaptation of muscle fibers to endurance vs. strength training is mediated by 
different firing patterns of their respective motor neurons39. Type I and IIa-specific gene 
expression patterns are achieved by frequent bursts of sarcoplasmic calcium with low 
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amplitude, as seen in endurance training. Strength training results in intermittent rises in 
sarcoplasmic calcium with high amplitude; this promotes transcription of the genes that 
mediate a type IIb-specific response and fiber hypertrophy39. Elevated sarcoplasmic 
calcium, in turn, activates the protein phosphatase calcineurin A (CnA) and the 
calcium/calmodulin-dependent protein kinases (CaMK), which then alter the 
phosphorylation state of multiple transcription factors and coactivators40. 
This heightened calcium signalling activates several important transcription 
factors: cAMP responsive element binding protein (CREB), the myocyte enhancer 
factors 2 (MEF2C and MEF2D) and the nuclear factor of activated T cells (NFAT). 
This results in altered expression of exercise-regulated muscle genes, particularly the 
powerful transcriptional coactivator PGC-1α41. Accordingly, PGC-1α expression is 
rapidly induced by these proteins following a single bout of endurance exercise in 
vivo42. When physical activity is stopped, PGC-1α mRNA and protein levels quickly 
revert to the pre-exercised quantity42. In acute bouts of exercise, it is likely that  
increased expression of PGC-1α is primarily a mechanism for modulating metabolic 
fluxes in skeletal muscle as a response to decreased ATP and altered fuel demands43. 
The multi-faceted interaction of PGC-1α with the AMP-activated protein kinase 
(AMPK) is likely to play a major role in this process44. In contrast, PGC-1α is found at 
an elevated level in chronically exercised skeletal muscle, even between individual 
bouts of exercise, when compared to untrained muscle45. This reflects short term vs. 
long term adaptation of skeletal muscle to endurance exercise.  
Thus, changes in muscle plasticity induced by chronic exercise, for example fiber-
type switching towards the more oxidative and high endurance type IIa and type I 
fibers, correlate with an increased basal expression of PGC-1α45. Furthermore, higher 
levels of PGC-1α are found in oxidative fibers compared to glycolytic fibers, even in a 
rested state46. Transgenic elevation of PGC-1α in the skeletal muscle of animals up to 
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the levels seen in type I fibers results in a stable and robust fiber-type switch towards 
both type IIa and type I oxidative fibers46. Individual muscle fibers from these mice are 
more fatigue resistant, compared to fibers from wild type animals, and transgenic 
animals perform better in endurance exercise indicating that chronic elevation of PGC-
1α mediates many, if not all of the phenotypic changes seen in endurance-trained 
muscle46,47. The fiber switch promoted by PGC-1α is characterized by increased 
mitochondrial density and function, increased oxidative metabolism, elevated 
expression of myofibrillar proteins characteristic of type I and type IIa muscle fibers 
and a switch in substrate fuel usage46,48. Conversely, animals with PGC-1α specifically 
ablated from skeletal muscle exhibit a higher number of glycolytic muscle fibers and 
have a reduced endurance exercise capacity49. Taken together, it is clear that PGC-1α is 
a key mediator of many of the known beneficial effects of physical activity on skeletal 
muscle physiology50,51. 
Protective effects of PGC-1α in muscle biology: Suppression of chronic 
inflammation and muscle catabolism 
One of the most important effects of exercise in human health is to prevent muscle 
catabolism and muscle wasting. Limb immobilization, prolonged hospitalization and 
various muscular dystrophies are conditions where developing an exercised muscle 
phenotype by the patient would improve the disease and the overall quality of life - but 
these patients often cannot train effectively. Several studies indicate that PGC-1α 
prevents protein catabolism and muscle wasting in a number of different contexts. 
Denervation-induced muscle atrophy, Duchenne muscular dystrophy and muscle 
damage via treatment with statin drugs are all greatly ameliorated when PGC-1α levels 
are maintained or elevated52-54. 
The precise mechanisms by which PGC-1α mediates these beneficial effects are 
not yet clear, but several possibilities exist (Fig. 3). Elevation of mitochondrial and 
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other metabolic genes, and the resulting correction of the energy crisis associated with 
muscular dystrophies44,55 are obvious and plausible mechanisms. In addition, reduction 
of atrophy-specific gene transcription by inhibition of FoxO3 activity54, increase in the 
gene program for protein synthesis54,56, and stabilization of the postsynaptic side of the 
neuromuscular junction (NMJ)53 also are likely to contribute to the anti-muscle wasting 
effect of PGC-1α. In particular, regulation of genes that encode the post-synaptic NMJ 
by PGC-1α has the potential to ameliorate the pathologies of neuromuscular diseases 
with decreased NMJ functionality, even those based on primary defects in the motor 
neuron. 
A key observation with potential relevance to a much broader set of chronic 
diseases arose from detailed studies of the animals with muscle-specific ablation of 
PGC-1α49,57. These showed that loss of PGC-1α specifically in muscle causes a 
transcriptional induction in muscle for many genes that can be part of local or systemic 
inflammation49,57. In particular, increased expression of inflammatory marker genes 
such as IL-6, TNFα, suppressor of cytokine signalling 1 (SOCS1), SOCS3 and CD68 
was observed in skeletal muscle of muscle-specific PGC-1α knockout animals in 
vivo49,57. Mice heterozygous for PGC-1α showed a smaller but significantly elevation 
expression of many of these same pro-inflammatory genes57. In both cases, chronic 
elevation of circulating IL-6 was observed57. Primary muscle cells with a genetic 
ablation of PGC-1α exhibit higher levels of TNF-α and IL-6 mRNA than wild type 
myotubes57 and elevated IL-6 protein was observed in the culture medium of the PGC-
1α knockout cells compared to control cells57. Conversely, adenoviral expression of 
PGC-1α in C2C12 myotubes in culture reduced the expression of TNFα and IL-6 
mRNA57. These data strongly suggest that at least part of the circulating pro-
inflammatory cytokines in vivo with ablation of PGC-1α is originating from the muscle 
cells themselves. Of course, amplification of this program may well involve subsequent 
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recruitment to muscle of immune cells that are “specialists” at amplifying a pro-
inflammatory response. 
Importantly, mice with a heterozygous mutation in PGC-1α in muscle have a 
reduction in mRNA expression of this coactivator that is quantitatively comparable to 
the transcriptional dysregulation of 36% observed in muscle of type 2 diabetic humans 
compared to healthy volunteers58,59. Furthermore, the drop in PGC-1α expression in 
muscle-specific heterozygous animals57 and skeletal muscle of type 2 diabetic 
patients59, respectively, corresponds quantitatively to the decreased expression of PGC-
1α in an inactive vs. an active muscle in mice54. Although the establishment of causality 
between these reduced expression of PGC-1α and the expression of pro-inflammatory 
genes is not possible in humans, these patients do also exhibit increased transcription of 
pro-inflammatory genes such as IL-6 and TNFα in skeletal muscle, as well as elevated 
IL-6 serum concentration57. Thus, the reduction of PGC-1α mRNA in skeletal muscle 
of type 2 diabetics is likely to be closely linked to the chronic, low-grade inflammation 
present in these patients. Finally, the lower PGC-1α levels observed in the muscle of 
pre-diabetic individuals likely contributes to increases in systemic IL-6, a strong 
predictor for the development of type 2 diabetes60. Indeed, skeletal muscle PGC-1α 
levels correlate inversely with expression of IL-6 and TNFα in individuals with normal 
glucose tolerance and in type 2 diabetic patients57. In contrast, body mass index, fasting 
glucose and fasting insulin levels exhibit no significant correlation to these 
inflammatory markers in this population57. Taken together, these finding also strongly 
suggest a causal relationship between the increases in PGC-1α expression  observed in 
human skeletal muscle following physical activity and the reduction of cytokine release 
from skeletal muscle known to occur with moderate exercise. Conversely, the effects of 
loss of even one allele of the PGC-1α gene in mice, which stimulates the expression of 
a broad program of cytokine expression and release, strongly suggests that something 
very similar is occurring in humans who engage in chronically sedentary behavior. 
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Accordingly, PGC-1α muscle-specific knockout animals exhibit decreased exercise 
capacity and a fiber-type switch towards glycolytic muscle fibers49. 
The molecular mechanisms that link PGC-1α and inflammatory gene expression 
in muscle are unknown, but they may reflect the role of PGC-1α in the control of 
reactive oxygen species (ROS). It has previously been shown that PGC-1α has a 
powerful suppressive effect on ROS production, in parallel to its effects in elevating 
mitochondrial respiration. This occurs through the PGC-1α-mediated expression of 
genes involved in ROS detoxification, as well as the expression of uncoupling proteins 
that can attenuate ROS production61,62. In fact, increased oxidative stress and 
inflammation are well-known to go hand in hand in many skeletal muscle-associated 
diseases63. Specifically, ROS have been shown to induce pro-inflammatory cytokine 
production in skeletal muscle64. Thus, the decreased expression of the anti-ROS genes 
in muscle-specific PGC-1α knockouts57 are very likely to make a substantial 
contribution to the increases seen in cytokine expression. Obviously though, there may 
be additional, more directs effects of PGC-1α on the expression of genes with either 
pro- or anti-inflammatory action. 
Analysis of muscle-specific PGC-1α knockout animals revealed that 
dysregulation of PGC-1α in skeletal muscle does not cause insulin resistance in this 
tissue per se, but precipitates abnormal whole body glucose and insulin homeostasis due 
to reduced insulin levels and abnormal pancreatic islet morphology. This unexpected, 
distal signalling apparently results from a noxious cross-talk between skeletal muscle 
and pancreatic β-cells in these animals57. Elevation of systemic inflammation is one 
likely mechanism by which skeletal muscle with dysregulated PGC-1α expression 
modulates β-cell function: elevation of IL-6 in the blood of PGC-1α muscle-specific 
knockout animals correlates with the ability of IL-6 to suppress glucose-stimulated 
insulin secretion in isolated islets57. These data indicate unambiguously that the levels 
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of skeletal muscle PGC-1α can powerfully influence the function of pancreatic islets; 
inescapably, these same data also suggest that muscle PGC-1α levels likely affect the 
structure and functions of other tissues and organs too. 
Systemic effects of exercise and PGC-1α 
We suggest here that the decrease in PGC-1α gene expression in skeletal muscle due to 
sedentary behavior can set off a low level but chronic pro-inflammatory response that 
impacts many other tissues negatively. As noted above, many if not most chronic 
diseases of aging, including heart disease, cancer and neurodegeneration are associated 
with chronic inflammation. In many cases that association has been shown to be causal 
in defined experimental systems. The suppression of chronic inflammation in muscle 
via exercise-mediated induction of PGC-1α gene expression would be expected to 
lower the frequency and/or severity of these very same disorders. In terms of clinical 
data, exercise has many neurological benefits, most notably improvement of learning 
and memory, protection against neurodegeneration and amelioration of depression as 
well as other mood disorders17. Cancer of the colon, breast, prostate, endometrium, 
pancreas and skin all exhibit an increased incidence in inactive individuals, compared to 
those who exercise1,65. Thus, multi-organ health and plasticity as a result of exercise 
might be strongly influenced by altered systemic inflammation controlled by skeletal 
muscle PGC-1α activity. 
It is important to note that it is very unlikely that any of the chronic diseases being 
discussed here are caused by reduced PGC-1α alone. Rather, these are multi-factorial 
diseases requiring multiple hits to yield full-blown disease. The multi-hit nature of 
human cancer now serves as useful conceptual model for most chronic diseases. These 
multiple insults may originate in the genetic heritage of an individual patient, may be 
acquired due to spontaneous somatic mutations, and may also be brought about by 
environmental or lifestyle factors. Thus, variables such as sedentary behavior and 
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reduced PGC-1α levels in muscle may be viewed, on a population basis, as shifting the 
likelihood of disease to the left on a standard plot of incidence vs. age, compared to 
individuals with average exercise/physical activity (Fig 4). For any given individual, it 
is difficult or impossible to know what impact sedentary behaviour had on their risk for 
cancer or brain disease, for example. But that it does have an impact on the total 
population is a certainty. Conversely, populations with above average physical activity 
and thus increased PGC-1α levels experience a reduced incidence of disease, relative to 
those with average activity and PGC-1α. 
Obesity: A most dangerous co-conspirator 
Sedentary behavior often coexists with and is a contributing factor in the development 
of obesity1,66,67. Conversely, obese individuals are less likely to exercise66,67. 
Furthermore, inactivity and obesity are independent risk factors for many of the same 
chronic diseases. In fact, inactivity worsens the prevalence of chronic diseases in 
individuals regardless of their BMI. Thus, being an independent risk factor, inadequate 
physical activity exacerbates the detrimental effects of obesity1. In keeping with the 
mechanisms discussed above, we predict a negative interaction between the lack of 
exercise and obesity in the specific molecular programs discussed here. Obesity has 
been strongly associated with the expression of a pro-inflammatory program of gene 
expression including TNFα, IL-1 and IL-610. More precisely, it has been known for 
more than a decade that adipose tissue, in the context of obesity, begins to secrete 
elevated levels of these “adipokines”68,69. This is true in both rodents and humans70,71. 
Moreover, a functional role for TNFα and other adipokines has been shown in the 
insulin-resistance of obese mice10. If we assume that there is a quantitative threshold of 
cytokines required both chronically and systemically to bring about pathology in other 
(non-adipose, non-muscle) tissues, then inactivity combined with obesity is much more 
likely to reach such a threshold (Fig 4). Furthermore, if the age of onset of a particular 
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disease, or the extent of disease is dose-responsive with respect to the levels of systemic 
pro-inflammatory molecules, obesity with sedentary behavior would be expected to 
bring about earlier and/or more severe disease72. Lastly, we do not know the full array 
of specific cytokines necessary to contribute to the onset of any particular disease, but 
obesity and sedentary behavior may interact in ways that are not just quantitative. 
Indeed, they may bring together a particular combination of adipokines/myokines that 
act synergistically in the causation of disease. How big are the synergistic effects of 
obesity and sedentary behavior in humans? Like other modifiable factors such as 
smoking, diabetes and hypertension, obesity is predicted to reduce life expectancy 
between 1 to 5 years. In contrast, physical activity is estimated to add up to 5 years. 
Importantly, a composite lifestyle of healthy behaviours has been proposed to 
potentially add 10 years to the average life expectancy8,73. 
Conclusion and perspectives: testing the Hypothesis 
It is obvious from the hypotheses presented here that many aspects of the 
physiological and pathophysiological effects of modulating PGC-1α in skeletal muscle 
and other organs remain enigmatic. Even less is known about the functions and 
therapeutic potential of the other two members of this gene family, PGC-1β and PGC-1-
related coactivator (PRC). Similar to PGC-1α muscle-specific transgenic animals, 
ectopic expression of PGC-1β increases endurance exercise capacity; however, different 
mechanisms seem to control the exercise-like phenotype in these two animal models74. 
Alterations in the amount and/or activity of PGC-1α protein in muscle are likely to have 
future applications in the prevention and treatment of a number of diseases. 
Amelioration of disuse-induced muscle atrophy54, DMD53 and statin-mediated muscle 
wasting52 through PGC-1α has already been described in animal models. The potential 
role of skeletal muscle PGC-1α as a modulator of non-muscular diseases, as discussed 
here, is not known but these ideas are readily testable in experimental animal models. It 
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is hypothesized here that mice lacking one or both copies of the PGC-1α gene 
specifically in skeletal muscle will be more susceptible to cancer, heart and brain 
disease. For example, mutant mice can be treated with chemical carcinogens that cause 
cancer of the breast, colon and other tissues and the rate of tumor formation and 
progression can be determined quantitatively. Likewise, the same mutant strains of mice 
can be given challenges that induce heart failure, or certain kinds of neurodegeneration 
that model Parkinson’s disease or Alzheimer’s disease, and the rates of disease 
incidence and progression can be carefully monitored. 
Determination of the proper exercise regimens to protect from diseases linked to 
muscle-based inflammation will be important. But chemical modulation of the PGC-1α 
pathway in skeletal muscle is also of obvious significance. That PGC-1α gene 
expression can be modulated by drugs and drug-like compounds has been 
demonstrated56,75,76. In addition, a number of transcription factors that complex with 
PGC-1α in controlling skeletal muscle gene transcription are already known50,51 and 
may represent therapeutic targets. Co-activation of the estrogen-related receptor α 
(ERRα, official nomenclature NR3B1) specifies PGC-1α to induce the same 
mitochondrial oxidative phosphorylation genes that are dysregulated in muscle of type 2 
diabetic patients56. Pharmacological disruption of the interaction between these two 
proteins provokes a metabolic phenotype in cultured muscle cells resembling that of 
type 2 diabetic muscle in vivo56. These findings provide a lead as to how selectivity in 
targeting PGC-1α could be achieved77. If successful, therapeutic modulation of PGC-1α 
has a huge clinical potential for muscle wasting, sarcopenia, type 2 diabetes, muscular 
dystrophies and other very serious non-muscular chronic diseases. 
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Figure 1. Clinical consequences of a sedentary lifestyle. Inactivity is an 
independent risk factor for a number of chronic diseases regardless of age, 
gender, race and health. 
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Figure 2. Inflammation and chronic diseases. A persistent, low-grade 
inflammatory state of different tissues is linked to the development of  many 
chronic diseases. 
Figure 3. Protective effect of PGC-1α on skeletal muscle. The relative level 
of PGC-1α in skeletal muscle is determined by physical activity. PGC-1α, in 
turn, controls muscle fiber adaptation to exercise and confers a number of 
beneficial changes. As a result, a reduction of systemic inflammation is 
observed in exercised individuals, possibly mediated through elevation of PGC-
1α. In contrast, inactivity, and thus low skeletal muscle PGC-1α, results in a 
chronic inflammatory state and thereby causes serious pathological 
consequences. This inactivity-driven systemic inflammation is further 
exacerbated by obesity. 
Figure 4. Inactivity and obesity are independent risk factors in the etiology 
of chronic diseases. A theoretical depiction of how sedentary lifestyle and 
obesity lower the threshold for age of onset and disease incidence. Together, 
inactivity and obesity worsen the relative risk for developing chronic diseases. 
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